1. Generics Bulletin

Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Parent Company Invests Another $270m In Biocon Biologics After Earlier Allotment

 
• By Dean Rudge

Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.

Financing
Viatris will receive cash and equity for its biosimilars • Source: Shutterstock

With the clock continuing to tick on its $3.3bn acquisition of the global biosimilars business of Viatris, Biocon Biologics has finalized a deal to receive a INR22.06bn ($270m) investment from its parent company Biocon, Ltd. via an allotment of shares.

The equity financing comes on the heels of Biocon buying up INR30

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products